Long-term safety and efficacy of deferasirox (Exjade®) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease

To date, there is a lack of long-term safety and efficacy data for iron chelation therapy in transfusion-dependent patients with sickle cell disease (SCD). To evaluate the long-term safety and efficacy of deferasirox (a once-daily oral iron chelator), patients with SCD completing a 1-year, Phase II,...

Full description

Saved in:
Bibliographic Details
Main Authors: Vichinsky, Elliott, Bernaudin, Françoise, Forni, Gian Luca, Gardner, Renee, Hassell, Kathryn, Heeney, Matthew M, Inusa, Baba, Kutlar, Abdullah, Lane, Peter, Mathias, Liesl, Porter, John, Tebbi, Cameron, Wilson, Felicia, Griffel, Louis, Deng, Wei, Giannone, Vanessa, Coates, Thomas
Format: Artigo
Language:Inglês
Published: Blackwell Publishing Ltd 2011
Subjects:
Red Cells and Iron
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3170481/
https://ncbi.nlm.nih.gov/pubmed/21592110
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2141.2011.08720.x
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items